Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Mercury Pharma Group Ltd., Capital House, 85 King William Street, London EC4N 7BL, UK
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypersensitivity to aspirin, or other non-steroidal anti-inflammatory drugs
Patients with asthma, rhinitis or urticaria.
Not to be used on broken or damaged skin.
Apply with gentle massage only. Avoid contact with eyes, mucous membranes and inflamed or broken skin.
Discontinue if rash develops.
Hands should be washed immediately after use.
Not for use with occlusive dressings.
The label will state:
DO NOT USE MORE GEL THAN THE LABEL TELLS YOU TO.
Keep out of the sight and reach of children
For external use only.
If symptoms persist consult your doctor or pharmacist
Do not use if you are allergic to Ibuprofen or any of the ingredients, aspirin, or any other painkillers.
Consult your doctor or pharmacist before use if:
Not recommended for children under 12 years.
Oral NSAIDs, including ibuprofen, can sometimes be associated with renal impairment, aggravation of active peptic ulcers, and can induce allergic bronchial reactions in susceptible asthmatic patients. Although the systemic absorption of topically applied ibuprofen is less than for oral dosage forms, these complications can occur in rare cases. For these reasons, patients with an active peptic ulcer, a history of kidney problems or asthma should seek medical advice before using Ibuprofen gel as should patients already taking other painkillers.
Patients should seek medical advice if symptoms worsen or persist.
Patients should be advised against excessive exposure to sunlight of area treated in order to avoid possibility of photosensitivity.
Instruct patients not to smoke or go near naked flames – risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.
Non-steroidal anti-inflammatory drugs may interact with blood pressure lowering drugs, and may possibly enhance the effects of anticoagulants, although the chance of either of these occurring with a topically administered preparation is extremely remote. Concurrent aspirin or other NSAIDS may result in an increased incidence of adverse reactions.
Not to be used during pregnancy or breast-feeding.
Although no teratogenic effects have been demonstrated, ibuprofen should be avoided during pregnancy. The onset of labour may be delayed and the duration of labour increased.
Ibuprofen appears in breast milk in very low concentrations but is unlikely to affect breast fed infants adversely.
No data available.
Not relevant.
The following adverse reactions are classified by system organ class and ranked under heading of frequency using the following convention:
Uncommon (≥1/1,000 to <1/100)
Not known (Frequency cannot be estimated from the available data)
Very rarely, susceptible patients may experience the following side effects with ibuprofen, but these are extremely uncommon when ibuprofen is administered topically. If they occur, treatment should be discontinued:-
System Order Class | Frequency | Adverse effects |
---|---|---|
Immune system disorders | Uncommon | Hypersentivity1 |
Gastrointestinal disorders | Uncommon | Abdominal pain, Dyspepsia |
Renal and urinary disorders | Uncommon | Renal impairment2 |
Skin and subcutaneous tissue disorders | Not known | Photosensitivity reactions |
1 Hypersensitivity reactions have been reported following treatment with ibuprofen. These may consist of (a) non-specific allergic reaction and anaphylaxis (b) respiratory tract reactivity comprising of asthma, aggravated asthma, brochospasm or dyspnoea, or © assorted skin disorders, including rashes of various types, pruritis, urticaria, purpura, angioedema and less commonly, bullous dermatoses (including epidermal necrolysis and erythema multiforme).
2 Renal impairment can occur in patients with a history of kidney problems.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.